Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma

BACKGROUND: Basal cell carcinoma (BCC) is the most common malignancy worldwide, yet the management of patients with advanced or metastatic disease is challenging, with limited treatment options. Recently, programmed death receptor 1 (PD-1) inhibition has demonstrated activity in BCC after prior Hedg...

Descripción completa

Detalles Bibliográficos
Autores principales: In, Gino Kim, Nallagangula, Aparna, Choi, Jacob Seung, Tachiki, Lisa, Blackburn, Matthew J, Capone, Stephen, Bollin, Kathryn B, Reuben, Daniel Y., Shirai, Keisuke, Zhang-Nunes, Sandy, Ragab, Omar, Terando, Alicia, Hu, Jenny C., Lee, Han, Bhatia, Shailender, Chandra, Sunandana, Lutzky, Jose, Gibney, Geoffrey Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096532/
https://www.ncbi.nlm.nih.gov/pubmed/35545318
http://dx.doi.org/10.1136/jitc-2022-004839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096532/
https://www.ncbi.nlm.nih.gov/pubmed/35545318
http://dx.doi.org/10.1136/jitc-2022-004839

Ejemplares similares